A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers

Trial Profile

A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs PF 5089771 (Primary)
  • Indications Pain
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Pharmacokinetics
  • Acronyms FIH SAD study
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Feb 2016 Results of two phase I studies published in the Clinical Pharmacokinetics
    • 30 Jan 2012 Actual patient number is 61 according to ClinicalTrials.gov.
    • 30 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top